Sep 15, 2020 7:00am EDT Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)
Sep 14, 2020 7:00am EDT Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors
Sep 10, 2020 7:00am EDT Matinas BioPharma to Participate on Anti-Fungal CEO Panel During the M-VEST Virtual Conference Series Sponsored by Maxim Group
Aug 27, 2020 4:05pm EDT Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®
Aug 26, 2020 7:00am EDT Matinas BioPharma to Participate in Two Upcoming Virtual Investor Conferences
Aug 20, 2020 7:00am EDT Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203
Aug 10, 2020 4:05pm EDT Matinas BioPharma Reports Second Quarter 2020 Financial Results and Operational Highlights
Jul 28, 2020 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2020 Financial and Operational Results on August 10, 2020
Jun 30, 2020 4:15pm EDT Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials
